These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 6157468

  • 1. Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma.
    Goldhirsch A, Pirovino M, Sonntag RW, Tschopp L, Ryssel HJ, Brunner KW.
    Cancer Treat Rep; 1980; 64(2-3):335-7. PubMed ID: 6157468
    [Abstract] [Full Text] [Related]

  • 2. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
    Canellos GP, Skarin AT, Rosenthal DS, Moloney WC, Frei E.
    Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
    [Abstract] [Full Text] [Related]

  • 3. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.
    Cancer; 2000 May 01; 88(9):2142-8. PubMed ID: 10813727
    [Abstract] [Full Text] [Related]

  • 5. Treatment of recurrent lymphomas with vincristine, BCNU, doxorubicin, and prednisone (VBAP): a Southwest Oncology Group Study.
    Weick JK, Jones SE, Haut A, Fisher R, Dixon D.
    Cancer Treat Rep; 1981 May 01; 65(7-8):611-4. PubMed ID: 6166373
    [Abstract] [Full Text] [Related]

  • 6. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
    O'Connell MJ, Anderson J, Merrill JM, Bennett JM, Glick JH, Berard CW, Neiman RS, Brodovsky HS.
    Cancer Treat Rep; 1982 Dec 01; 66(12):2021-5. PubMed ID: 6814757
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 Dec 01; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 8. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
    Anderson KC, Skarin AT, Rosenthal DS, MacIntyre JM, Pinkus GS, Case DC, Leonard RC, Canellos GP.
    Cancer Treat Rep; 1984 Nov 01; 68(11):1343-50. PubMed ID: 6209007
    [Abstract] [Full Text] [Related]

  • 9. Combination of vindesine and prednisone in malignant lymphoma and acute leukemia.
    Raich PC, Walker BK, Rogers JS, Subramanian VP, Fontana JA, Knost JA, Denning B.
    Cancer Treat Rep; 1983 May 01; 67(5):485-7. PubMed ID: 6573959
    [Abstract] [Full Text] [Related]

  • 10. [Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
    Sampi K, Honda T, Hattori M, Takayama S.
    Gan To Kagaku Ryoho; 1983 May 01; 10(5):1266-71. PubMed ID: 6191677
    [Abstract] [Full Text] [Related]

  • 11. [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
    Sampi K, Honda T, Hattori M.
    Gan To Kagaku Ryoho; 1984 May 01; 11(5):1012-7. PubMed ID: 6202245
    [Abstract] [Full Text] [Related]

  • 12. Advanced diffuse histiocytic lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) without maintenance therapy.
    Armitage JO, Corder MP, Leimert JT, Dick FR, Elliot TE.
    Cancer Treat Rep; 1980 May 01; 64(4-5):649-54. PubMed ID: 7000347
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.
    Cancer J; 2000 May 01; 6(3):146-50. PubMed ID: 10882329
    [Abstract] [Full Text] [Related]

  • 14. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study.
    Grozea PN, Jones SE, McKelvey EM, Coltman CA, Fisher R, Haskins CL.
    Cancer Treat Rep; 1979 Apr 01; 63(4):647-53. PubMed ID: 87277
    [Abstract] [Full Text] [Related]

  • 15. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R.
    Cancer Treat Rep; 1984 Apr 01; 68(7-8):947-51. PubMed ID: 6204754
    [Abstract] [Full Text] [Related]

  • 16. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
    Chiuten DF, Bennett JM, Creech RH, Glick J, Falkson G, Brodovsky HS, Begg CB, Muggia FM, Carbone PP.
    Cancer Treat Rep; 1979 Jan 01; 63(1):7-11. PubMed ID: 369693
    [Abstract] [Full Text] [Related]

  • 17. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.
    Clin Cancer Res; 2006 Jan 15; 12(2):529-35. PubMed ID: 16428496
    [Abstract] [Full Text] [Related]

  • 18. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Oct 01; 21(19):3601-8. PubMed ID: 12913100
    [Abstract] [Full Text] [Related]

  • 19. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul 01; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 20. [Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].
    Parlier Y, Gorin NC, Stachowiak J, Najman A, Duhamel G.
    Sem Hop; 2001 Jul 01; 57(41-42):1685-90. PubMed ID: 6272402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.